Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Summit Therapeutics (SMMT) over the last 10 years, with Q3 2025 value amounting to -$93.1 million.

  • Summit Therapeutics' Cash from Operations fell 20722.51% to -$93.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$269.7 million, marking a year-over-year decrease of 13886.99%. This contributed to the annual value of -$142.1 million for FY2024, which is 8513.03% down from last year.
  • Summit Therapeutics' Cash from Operations amounted to -$93.1 million in Q3 2025, which was down 20722.51% from -$66.7 million recorded in Q2 2025.
  • Summit Therapeutics' 5-year Cash from Operations high stood at $5.2 million for Q4 2022, and its period low was -$93.1 million during Q3 2025.
  • In the last 5 years, Summit Therapeutics' Cash from Operations had a median value of -$20.7 million in 2021 and averaged -$29.2 million.
  • As far as peak fluctuations go, Summit Therapeutics' Cash from Operations surged by 15655.3% in 2022, and later plummeted by 47486.03% in 2023.
  • Over the past 5 years, Summit Therapeutics' Cash from Operations (Quarter) stood at -$9.2 million in 2021, then surged by 156.55% to $5.2 million in 2022, then crashed by 474.86% to -$19.5 million in 2023, then crashed by 150.13% to -$48.7 million in 2024, then plummeted by 91.24% to -$93.1 million in 2025.
  • Its Cash from Operations stands at -$93.1 million for Q3 2025, versus -$66.7 million for Q2 2025 and -$61.2 million for Q1 2025.